Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

NefIgArd Trial Investigators

Research output: Contribution to journal › Article › peer-review

81 Scopus citations

Fingerprint

Dive into the research topics of 'Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy'. Together they form a unique fingerprint.

Medicine & Life Sciences